登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式(希尔记法):
C26H26ClN3 · C4H4O4
化学文摘社编号:
分子量:
532.03
UNSPSC Code:
51111800
NACRES:
NA.77
MDL number:
SMILES string
Clc1cc2c(cc1)C(=C4CCN(CC4)Cc5cncc(c5)C)c3ncccc3CC2.OC(=O)\C=C\C(=O)O
InChI
1S/C26H26ClN3.C4H4O4/c1-18-13-19(16-28-15-18)17-30-11-8-20(9-12-30)25-24-7-6-23(27)14-22(24)5-4-21-3-2-10-29-26(21)25;5-3(6)1-2-4(7)8/h2-3,6-7,10,13-16H,4-5,8-9,11-12,17H2,1H3;1-2H,(H,5,6)(H,7,8)/b;2-1+
InChI key
JYBLCDXVHQWMSU-WLHGVMLRSA-N
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
2-8°C
Quality Level
正在寻找类似产品? 访问 产品对比指南
Biochem/physiol Actions
Rupatadine (UR-12592) is an orally active, dual histamine H1 and platelet-activating factor (PAF) receptor antagonist (Ki(app) = 100/550 nM against pyrilamine/WEB2086 binding to guinea pig cerebellum/rabbit platelet membranes) that inhibits histamine-induced guinea pig ileum contraction (pA2 = 9.29) and PAF-induced platelet aggregation (IC50 = 0.68 μM/human PRP). Rupatadine blocks histamine-/PAF-induced hypotension (ID50 = 1.4/0.44 mg/kg i.v. rats) and bronchoconstriction (ID50 = 113/9.6 μg/kg i.v. guinea pigs), as well as prevents mortality caused by PAF (ID50 = 0.31 mg/kg i.v. or 3.0 mg/kg p.o. mice) and endotoxin (mice/rats ID50 = 1.6/0.66 mg/kg i.v.) in vivo.
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
Xiao-xi Lv et al.
PloS one, 8(7), e68631-e68631 (2013-07-23)
A similar immune response is implicated in the pathogenesis of pulmonary fibrosis and allergic disorders. We investigated the potential therapeutic efficacy and mechanism of rupatadine, a dual antagonist of histamine and platelet-activation factor (PAF), in bleomycin- (BLM-) and silica-induced pulmonary
M Queralt et al.
Inflammation research : official journal of the European Histamine Research Society ... [et al.], 49(7), 355-360 (2000-08-26)
To examine the inhibitory potential of rupatadine, a new H1-antihistamine and anti-PAF agent, on histamine and TNF-alpha release. Comparison with an H1-antihistamine (loratadine) and a PAF-antagonist (SR-27417A). Dispersed canine skin mast cells were used to assess the effect of the
Heba M Hafez et al.
Naunyn-Schmiedeberg's archives of pharmacology, 393(8), 1487-1500 (2020-03-23)
The role of histamine and platelet activating factor (PAF) as involved mediators in the pathophysiology of diabetic complications, in particular diabetic nephropathy (DN), has become a new focus of concern. Accordingly, the present study designed to explore the effect of
R Caballero et al.
British journal of pharmacology, 128(5), 1071-1081 (1999-11-11)
1. The effects of rupatadine, a new dual antagonist of both histamine H1 and platelet-activating factor receptors, were studied on human cloned hKv1.5 channels expressed in Ltk- cells using the whole-cell patch-clamp technique. 2. Rupatadine produced a use- and concentration-dependent
Gathsaurie Neelika Malavige et al.
Scientific reports, 8(1), 3857-3857 (2018-03-03)
Currently there are no specific treatments available for acute dengue infection. We considered that rupatadine, a platelet-activating factor receptor inhibitor, might modulate dengue-associated vascular leak. The effects of rupatadine were assessed in vitro, and in a dengue model, which showed
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持